Cytomedix Inc. Announces Multiple Poster Presentations at the Symposium on Advanced Wound Care Spring 2012

GAITHERSBURG, MD--(Marketwire - April 18, 2012) - Cytomedix, Inc. (OTCBB: CMXI) (the “Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that three poster presentations highlighting the clinical merits of the Company’s AutoloGel™ System in wound management will be presented at the Symposium on Advanced Wound Care (“SAWC”) Spring 2012 to be held in Atlanta from April 19-22, 2012.

The AutoloGel System, a device for the production of autologous platelet rich plasma (“PRP”) gel, is the only PRP device cleared by the U.S. Food and Drug Administration (“FDA”) for use in wound management.

Poster presenters will be available Friday, April 20 from 7:30-9:00 a.m., and posters will be available for viewing Friday, April 20 and Saturday, April 21 from 7:30 a.m.-6:00 p.m. The following posters highlighting Cytomedix’s PRP technology will be presented at SAWC Spring 2012.

• Aged Spinal Cord Injury Veterans with Recalcitrant Pressure Ulcers Treated with Platelet-Rich Plasma Gel will be presented by Natalie Tukpah, RN, CWOCN and Karen Evans, MD, Veterans Affairs Medical Center, Washington DC. Poster Number CS-106

• Healing Complex, Severe Diabetic and Ischemic Wounds in Japan Using Platelet-Rich Plasma Gel will be presented by Chugo Rinoie, DPM, ABPO, CWS, Chief of Podiatric Surgery, Wound Healing Center, Methodist Hospital of Southern California, Arcadia, California. Poster Number CR-56

• Advancing Wound Healing Trajectory with Platelet Rich Plasma Gel in Stalled NPWT Wounds will be presented by Janice Wilson, RN, CWOCN and Karl Branch, RN, Asheville Specialty Hospital, Asheville, North Carolina. Poster Number CR-68
  

“We are especially pleased to have three posters at SAWC as it offers an ideal venue to reach and educate a large audience of clinicians who specialize in wound management on the clinical merits of AutoloGel to heal these challenging wounds. These data, collectively and individually, demonstrate the clinical utility of AutoloGel to heal a variety of hard-to-heal wounds in various clinical care settings,” commented Martin P. Rosendale, Chief Executive Officer of Cytomedix. “Compelling clinical results such as these should favorably impact the adoption of AutoloGel in a variety of wounds and wound care settings, and further support our formal request for reimbursement consideration from the Centers for Medicare & Medicaid Services.”

About Cytomedix, Inc.

Cytomedix, Inc. develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma (“PRP”) gel for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma (“PPP”) and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. On February 8, 2012 Cytomedix closed the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell (“ALDHbr”) technology, currently in a Phase 2 trial for the treatment of ischemic stroke. For additional information please visit www.cytomedix.com

Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix’ actual results may differ materially due to a number of factors, many of which are beyond Cytomedix’ ability to predict or control, including among many others, risks and uncertainties related to the Company’s ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company’s sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company’s ability to raise additional capital and to continue as a going concern, and Cytomedix’s ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as “believes”, “forecasted,” “projects,” “is expected,” “remain confident,” “will” and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at www.sec.gov.